Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 4 (6), 999-1001

Is Natalizumab a Breakthrough in the Treatment of Multiple Sclerosis?

Affiliations
Clinical Trial

Is Natalizumab a Breakthrough in the Treatment of Multiple Sclerosis?

Sheila A Doggrell. Expert Opin Pharmacother.

Abstract

In patients with either relapsing-remitting or secondary-progressive multiple sclerosis, there were fewer new lesions/patient with natalizumab (0.7 and 1.1 with natalizumab 3 and 6 mg/kg every 28 days, respectively) than in the placebo group (9.6 new lesions/patient) over 6 months. There were also fewer relapses in the natalizumab groups than the placebo group. However, there were no changes in the Expanded Disability Status Scale scores in any of the groups. Natalizumab was well-tolerated. Thus, the initial results with natalizumab treatment over 6 months in multiple sclerosis are encouraging.

Similar articles

See all similar articles

MeSH terms

LinkOut - more resources

Feedback